Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31736763 | 0.84 | ITGB1 (0.43) | PTPN1CTSBCTSSCTSLSLC6A3 | |
| SCHEMBL29406248 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL29370428 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL29385767 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL3736523 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL1514663 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL799706 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL29400401 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL29410226 | 0.81 | MDM4 (0.52) | PTPN1CTSBCTSSCTSLMDM4 | |
| SCHEMBL30918333 | 0.81 | PTPN1 (0.40) | PTPN1CTSBCTSSCTSLMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | PTPN1 3747/4885CTSB 1288/4885CTSS 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.